Evaluating the impact of public health notification of suspected transfusion-transmissible hepatitis C virus infection and effectiveness of lookback and traceback investigations by Canadian Blood Services in British Columbia, Canada, August 2002 through February 2005

Transfusion

Volumn 47, Issue 8, 2007, Pages 1534-1539

  Whitlock, Mandy ^b   Lord, Sandra ^b   Buxton, Jane A ^b   Doyle, Patrick ^b   Bigham, Mark ^a  

^a CANADIAN BLOOD SERVICES   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD BANK; BLOOD DONOR; CANADA; CONTROLLED STUDY; DATA ANALYSIS; DONOR SELECTION; ENZYME IMMUNOASSAY; HEPATITIS C; HUMAN; POSTTRANSFUSION HEPATITIS; PUBLIC HEALTH; SCREENING; TORQUE TENO VIRUS;

BLOOD DONORS; BLOOD TRANSFUSION; CANADA; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; PUBLIC HEALTH; TIME FACTORS;

EID: 34547114458     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01294.x     Document Type: Article

References (32)

1. Bigham M, Doyle P, Peck S. Newly reportable diseases in British Columbia. BC Med J 2002 44 : 294.
2. Communicable disease control, transfusion transmissible infection [monograph on the Internet]. Vancouver : BC Centre for Disease Control 2004 Jul [accessed 2005 Jul 7]. Available from: http://www.bccdc.org/download.php?item=44
3. Guidance for industry: supplemental testing and the notification of consignees of donor test results for antibody to hepatitis C virus (anti-HCV) [monograph on the Internet]. Rockville (MD) : U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration 1998 Mar [accessed 2006 Sep 9]. Available from: http://www.fda.gov/cber/gdlns/antihcv.htm
4. Vrielink H, van der Poel CL, Reesink HW, et al. Look-back study of infectivity of anti-HCV ELISA-positive blood components. Lancet 1995 345 : 95 6.
5. Christensen PB, Groenbaek K, Krarup HB. Transfusion-acquired hepatitis C: the Danish lookback experience. Danish HCV [hepatitis C virus] Lookback Group. Transfusion 1999 39 : 188 93.
6. Kike AE, Christie JM, Kurtz JB, Teo CG. Hepatitis C in blood transfusion recipients identified at the Oxford Blood Centre in the national HCV look-back programme. Transfus Med 1998 8 : 87 95.
7. Long A, Spurll G, Demers H, Goldman M. Targeted hepatitis C lookback: Quebec, Canada. Transfusion 1999 39 : 194 200.
8. Goldman M, Juodvalkis S, Gill P, Spurll G. Hepatitis C lookback. Transfus Med Rev 1998 12 : 84 93.
9. Goldman M, Spurll G. Hepatitis C lookback. Curr Opin Hematol 2000 7 : 392 6.
10. Menozzi D, Udulutch T, Llosa AE, Galel SA. HCV lookback in the United States: effectiveness of an extended lookback program. Transfusion 2000 40 : 1393 8.
11. Culver DH, Alter MJ, Mullan RJ, Margolis HS. Evaluation of the effectiveness of targeted lookback for HCV infection in the United States - interim results. Transfusion 2000 40 : 1153 6.
12. Callum JL, Pinkerton PH, Coovadia AS, Thomson AE, Dewsbury F. An evaluation of the process and costs associated with targeted lookbacks for HCV and general notification of transfusion recipients. Transfusion 2000 40 : 1169 75.
13. Goldman M, Long A. Hepatitis C lookback in Canada. Vox Sang 2000 78 (Suppl 2 249 52.
14. Bowker SL, Smith LM, Rosychuk RJ, Preiksaitis JK. A review of general hepatitis C virus lookbacks in Canada. Vox Sang 2004 86 : 21 7.
15. AuBuchon JP. Paving with good intentions: learning from HCV lookback [editorial]. Transfusion 2000 40 : 1153 6.
16. Goldman M, Patterson L, Long A. Recent Canadian experience with targeted hepatitis C virus lookback. Transfusion 2006 46 : 690 4.
17. Kleinman S, Alter H, Busch M, et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by multiple-antigen HCV enzyme immunoassay. Transfusion 1992 32 : 805 13.
18. Sharma UK, Stramer SL, Wright DJ, et al. Impact of changes in viral marker screening assays. Transfusion 2003 43 : 202 14.
19. Kleinman SH, Busch MP. The risks of transfusion-transmitted infection: direct estimation and mathematical modelling. Baillieres Best Pract Res Clin Haematol 2000 13 : 631 49.
20. Epstein J. Hepatitis C virus lookback: emerging science and public policy [editorial]. Transfusion 2000 40 : 3 5.
21. Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C virus infection in post-transfusion hepatitis: an analysis with first- and second-generation assays. N Engl J Med 1991 325 : 1325 9.
22. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Medical progress: transfusion medicine (first of two parts) - blood transfusion. N Engl J Med 1999 340 : 438 47.
23. Tobler LH, Stramer SL, Lee SR, et al. Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening. Transfusion 2003 43 : 1452 9.
24. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004 351 : 760 8.
25. Busch MP, Glynn SA, Wright DJ, et al. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection. Transfusion 2005 45 : 1853 63.
26. Vamvakas EC, Taswell HF. Epidemiology of blood transfusion. Transfusion 1994 34 : 464 70.
27. Silk BJ, Berkelman RL. A review of strategies for enhancing the completeness of notifiable disease reporting. J Public Health Manag Pract 2005 11 : 191 200.
28. Doyle TJ, Glynn MK, Groseclose SL. Completeness of notifiable infectious disease reporting in the United States: an analytic literature review. Am J Epidemiol 2002 155 : 866 74.
29. Konowitz PM, Petrossian GA, Rose DN. The underreporting of disease and physicians' knowledge of reporting requirements. Public Health Rep 1984 99 : 31 5.
30. Centers for Disease Control and Prevention (CDC). Progress in improving state and local disease surveillance - United States, 2000-2005. Morb Mortal Wkly Rep 2005 54 : 822 5.
31. Ward M, Brandsema P, van Straten E, Bosman A. Electronic reporting improves timeliness and completeness of infectious disease notification, The Netherlands, 2003. Euro Surveill 2005 10 : 27 30.
32. Buxton J, Forrester L, Bigham M, et al. Anonymized data linkage: a tool for maximizing blood safety while protecting individual privacy. Presented at the 96th CPHA Conference 2005 Sep 18-21 Ottawa, Canada.